We know that there is a 40% to 275% increased risk when patients are on those medications. The CNISP program has been reviewing this for a number of years. They haven't been collecting data on the medications the patients are on at admission. That's an issue I've raised with the department before.
Do you feel, Dr. Beaudet, or the two of you as clinicians, that in fact collecting data would help clarify the role of proton pump inhibitors in contributing to C. difficile cases?